JP2024527043A5 - - Google Patents
Info
- Publication number
- JP2024527043A5 JP2024527043A5 JP2024504950A JP2024504950A JP2024527043A5 JP 2024527043 A5 JP2024527043 A5 JP 2024527043A5 JP 2024504950 A JP2024504950 A JP 2024504950A JP 2024504950 A JP2024504950 A JP 2024504950A JP 2024527043 A5 JP2024527043 A5 JP 2024527043A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- variable region
- chain variable
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/109028 | 2021-07-28 | ||
| CN2021109028 | 2021-07-28 | ||
| CNPCT/CN2022/103725 | 2022-07-04 | ||
| CN2022103725 | 2022-07-04 | ||
| PCT/US2022/074284 WO2023010098A2 (en) | 2021-07-28 | 2022-07-28 | Novel multi-specific molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527043A JP2024527043A (ja) | 2024-07-19 |
| JP2024527043A5 true JP2024527043A5 (cg-RX-API-DMAC7.html) | 2025-08-04 |
Family
ID=85088266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024504950A Pending JP2024527043A (ja) | 2021-07-28 | 2022-07-28 | 新規多重特異性分子 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240336686A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4377357A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024527043A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240039005A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118055946A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022319934A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3226306A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024001328A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202311296A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023010098A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3196930A1 (en) * | 2020-09-28 | 2022-03-31 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel anti-claudin18 antibodies |
| CN120569409A (zh) * | 2023-01-18 | 2025-08-29 | 科望(苏州)生物医药科技有限公司 | 靶向sirpa和claudin 18.2的双特异性分子 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018223182A1 (en) * | 2017-06-05 | 2018-12-13 | The Council Of The Queensland Institute Of Medical Research | A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf- kb ligand) antagonist for cancer therapy or prophylaxis and uses therefor. |
-
2022
- 2022-07-28 AU AU2022319934A patent/AU2022319934A1/en active Pending
- 2022-07-28 CN CN202280052987.4A patent/CN118055946A/zh active Pending
- 2022-07-28 MX MX2024001328A patent/MX2024001328A/es unknown
- 2022-07-28 JP JP2024504950A patent/JP2024527043A/ja active Pending
- 2022-07-28 US US18/292,921 patent/US20240336686A1/en active Pending
- 2022-07-28 CA CA3226306A patent/CA3226306A1/en active Pending
- 2022-07-28 WO PCT/US2022/074284 patent/WO2023010098A2/en not_active Ceased
- 2022-07-28 EP EP22850531.9A patent/EP4377357A4/en active Pending
- 2022-07-28 KR KR1020247006210A patent/KR20240039005A/ko active Pending
- 2022-07-28 TW TW111128254A patent/TW202311296A/zh unknown